Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01958528 · ClinicalTrials.gov registry record
Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM
A clinical trial of a Diagnosis of MGUS or SMM by IMWG Criteria, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 52
- Enrollment target
- 1
- Study location
NCT01958528: Completed study of a Diagnosis of MGUS or SMM by IMWG Criteria, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01958528 is a study of a Diagnosis of MGUS or SMM by IMWG Criteria that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 52 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01958528, a study of a Diagnosis of MGUS or SMM by IMWG Criteria, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study to collect blood and bone marrow samples from patients with SM and MGUS. About 100 subjects will be enrolled at the University of Pennsylvania and followed for 2 years. The primary objective of this study is to evaluate CMMCs as a biomarker to detect patients at high risk of progression to multiple myeloma in patients with MGUS and SMM.
Conditions Studied
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-05-23 |
| Est. Completion | 2019-01-22 |
What the finished NCT01958528 record still lists
NCT01958528 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 1 condition, with a Diagnosis of MGUS or SMM by IMWG Criteria appearing as the primary indexed condition, and to 0 interventions.
NCT01958528 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01958528 about?
NCT01958528 is a clinical study titled "Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM". This is a prospective study to collect blood and bone marrow samples from patients with SM and MGUS. About 100 subjects will be enrolled at the University of Pennsylvania and followed for 2 years. The primary objective of this study is to evaluate CMMCs as a biomarker to detect patients at high risk...
What is the current status of trial NCT01958528?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2013-05-23. Estimated completion is 2019-01-22.
What conditions does trial NCT01958528 study?
This clinical trial studies the following conditions: a Diagnosis of MGUS or SMM by IMWG Criteria.
Who is sponsoring clinical trial NCT01958528?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01958528 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI